Page d'accueil
|
Aide
|
Effacer
Anglais
|
Français
Rechercher
|
Catégories
|
Titres A-Z
|
Pays
|
Comparer pays
|
Index
Etendre sommaire
Document complet
Dérouler chapitre
Préférences
Version HTML imprimable
Exporter le document en format HTML
Aide
Guidelines to Antiretroviral Drug Therapy in Kenya
(WHO; 2001; 78 pages)
FOREWORD
ACKNOWLEDGMENT
CHAPTER ONE: INITIATING ANTIRETROVIRAL THERAPY
1.1 Introduction
1.2 Guidelines to making a diagnosis of HIV infection
1.3 Laboratory Diagnosis of HIV infection
1.4 Goals of therapy
1.5 When to start therapy
1.6 Risks and benefits of delayed initiation of therapy and of early therapy in the Asymptomatic HIV-Infected Patient
1.7 Antiretroviral profile
1.8 What drug combination to start with?
CHAPTER TWO: MONITORING AND CHANGING THERAPY
2.1 Surrogate markers
2.2 Resistance testing
2.3 How often should CD4 Cell Count and Viral Load be performed (Frequency)
2.4 Treatment failure
2.5 Reasons for non-adherence
2.6 Considerations for changing a failing regimen
2.7 Guidelines for changing an antiretroviral regimen for suspected drug failure
2.8 Potential options for changing therapy*
CHAPTER THREE: PHARMACOTHERAPEUTICS OF ARVS
3.1 Characteristics of available antiretroviral drugs
3.2 Pharmacokinetic properties of Antiretrovirals
CHAPTER FOUR: GUIDELINES FOR THE USE OF ANTIRETROVIRAL DRUGS IN PAEDIATRIC HIV INFECTION
4.1 Overview
4.2 Diagnosis of HIV infection in children
4.3 When to initiate treatment
4.4 Initiation of treatment
4.5 Agents to choose for initial treatment
4.6 Dosages for paediatric formulations
4.8 Monitoring
4.9 When to change therapy
CHAPTER FIVE: MANAGEMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTED PREGNANT WOMEN AND PREVENTION OF MOTHER TO CHILD TRANSMISSION (MTCT) OF HIV
5.1 Overview
5.2 Factors affecting mother to child transmission
5.3 Outline antenatal, intrapartum postpartum and postnatal care
5.4 Antiretroviral Therapy to prevent MTCT
CHAPTER SIX: SPECIAL CONSIDERATIONS
6.1 Acute retroviral syndrome (ARVS)
6.2 ARV drugs and the treatment of Tuberculosis
6.3 Immune recovery syndrome
CHAPTER SEVEN: WHEN TO STOP TREATMENT (INTERRUPTIONS)
7.1 Structured treatment interruptions (STI's)
7.2 Non structured treatment interruption
CHAPTER EIGHT: GUIDELINES FOR POST EXPOSURE PROPHYLAXIS
8.1 Treatment of exposure sites
8.2 Timing of post - HIV exposure prophylaxis initiation
8.3 Assessment of exposure risk
8.4 Post - HIV exposure prophylaxis
8.5 Recommended HIV serology after exposure
8.6 Management of health care workers with accidental exposure to HIV infection
8.7 Management of hospital staff with sharp injury or exposure to blood and body fluids
8.8 Management of non occupational exposure to HIV infection
8.9 Management of non-sexual and non occupational Exposures to HIV
CHAPTER NINE: ACCESS TO DRUGS IN KENYA
APPENDICES
I. Drug to drug interactions
II. Drug to drug interactions (continued)
III. Drug Interactions Between Antiretrovirals and Other Drugs
IV. Nucleoside Reverse Transcriptase Inhibitors (NRTIS)
V. Drug Interactions: Protease Inhibitors
VI. Drug Interactions: Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors - Cont.
VII. Drug That Should Not be Used With Antiretrovirals
VIII. Drugs that should not be used with Protease Inhibitors Antiretrovirals
IX. HIV-related drugs with overlapping toxicities
X. Anti-retroviral therapy for preventing MTCT
BACK COVER
CHAPTER FIVE: MANAGEMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTED PREGNANT WOMEN AND PREVENTION OF MOTHER TO CHILD TRANSMISSION (MTCT) OF HIV
S'il vous plaît envoyez vos commentaires
Anglais
| Français
